{
    "organizations": [],
    "uuid": "59c8447a9681970590e1ca28907959f1c134df3a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-karyopharms-selinexor-receives-fas/brief-karyopharms-selinexor-receives-fast-track-designation-from-fda-idUSASC09VDB",
    "ord_in_thread": 0,
    "title": "BRIEF-Karyopharm's Selinexor Receives Fast Track Designation From FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 27 AM / Updated 12 minutes ago BRIEF-Karyopharm's Selinexor Receives Fast Track Designation From FDA Reuters Staff 1 Min Read \nApril 10 (Reuters) - Karyopharm Therapeutics Inc: \n* KARYOPHARMâ€™S SELINEXOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA \n* EXPECTS TO REPORT TOP-LINE DATA FROM STORM STUDY AT END OF APRIL 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T14:26:00.000+03:00",
    "crawled": "2018-04-10T14:45:47.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "selinexor",
        "receives",
        "fast",
        "track",
        "designation",
        "fda",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "karyopharm",
        "therapeutic",
        "inc",
        "karyopharm",
        "selinexor",
        "receives",
        "fast",
        "track",
        "designation",
        "fda",
        "treatment",
        "patient",
        "multiple",
        "myeloma",
        "expects",
        "report",
        "data",
        "storm",
        "study",
        "end",
        "april",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}